Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US7145057

Title:Chimeric bird from embryonic stem cells
Inventors:Etches, Robert J.; San Mateo, CA, USA
Heyer, Babette; Menlo Park, CA, USA
Diamond, Jennifer; Millbrae, CA, USA
Mather, Christine; Millbrae, CA, USA
Beemer, Kathleen; Pacifica, CA, USA
Myers, Heather; Danville, CA, USA
Summary:This invention introduces novel cultures of avian embryonic stem cells. Methods are described by which the avian embryonic stem cells are injected into recipient embryos to yield chimeras with a significant contribution of original phenotype from the original stem cell. Further disclosed are means by which transgene encoding exogenous proteins are stably integrated in the embryonic stem cells and are present in the somatic tissue of the resulting chimeras. Such transgenes may encode exogenous proteins expressed in endodermal, ectodermal, mesodermal, or extra embryonic tissue. The authors describe methods by which breeding the resulting chimera yields transgenic birds whose genome is comprised of exogenous DNA.
Abstract:Sustained cultures of avian embryonic stem cells are provided. Injection of avian embryonic stem cells into recipient embryos yields chimeras with a significant contribution from the embryonic stem cell phenotype. Transgene encoding exogenous proteins are stably integrated in the embryonic stem cells and are present in the somatic tissue of the resulting chimeras. The transgenes may encode exogenous proteins expressed in endodermal, ectodermal, mesodermal, or extra embryonic tissue. Breeding the resulting chimera yields transgenic birds whose genome is comprised of exogenous DNA.
US Patent Website:Click Here for Full Text of Patent
Title Number:US7145057
Application Number:US2002000067148
Date Filed:01/02/2002
Date Published:15/12/2006
Assignee:Origen Therapeutics, Inc., Burlingame, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021